BIOQUEST CORP. Financials (USD)
| Sales 2021 | - | Sales 2022 | - | Capitalization | 5.88M |
|---|---|---|---|---|---|
| Net income 2021 | -2M | Net income 2022 | - | EV / Sales 2021 | - |
| Net Debt 2021 | 0.07 | Net Debt 2022 | 0.15 | EV / Sales 2022 | - |
| P/E ratio 2021 |
-3.56
x | P/E ratio 2022 |
-6.42
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 11.33% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 19-11-17 | |
David Noyes
DFI | Director of Finance/CFO | 81 | 19-09-30 |
Michael L. Krall
PSD | President | 72 | 19-10-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael L. Krall
PSD | President | 72 | 19-10-09 |
| Chief Executive Officer | 67 | 19-11-17 | |
Robert Orbach
BRD | Director/Board Member | 69 | 19-10-09 |
Bioquest Corp. is primarily focused on acquiring companies in the green energy sector. The Company has executed a letter of intent to acquire all of the issued and outstanding shares of Progressus Clean Technologies, Inc. (Progressus), which is a private company. Progressus is a venture stage green technology company focused on the development of hydrogen generation and separation technologies. Progressus owns the rights to intellectual property that enables the extraction of dilute amounts of hydrogen at purity from a various gas stream. The Company has not generated any revenue.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +18.70% | 42.77B | |
| +20.29% | 22.23B | |
| +13.05% | 14.44B | |
| +10.68% | 13.05B | |
| +34.29% | 11.59B | |
| -8.60% | 6.95B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +5.03% | 4.97B |
